Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: J Neuropathol Exp Neurol. 2015 Dec;74(12):1158–1169. doi: 10.1097/NEN.0000000000000262

Figure 6.

Figure 6

Glial fibrillary acidic protein (GFAP) and apoptosis. Transgenic mice injected with sarkosyl-insoluble Lewy body disease (LBD) brain homogenate displayed a widespread increase in GFAP immunoreactivity (A) with intense staining at the substantia nigra (boxed area), compared with transgenic mice injected with sarkosyl-insoluble control brain which appeared to have lower GFAP burdens (B). Transgenic mice injected with sarkosyl-insoluble LBD brain homogenate did not show evidence of apoptosis using an apoptosis kit (C, hippocampus). The proprietary positive control demonstrated staining in treated hippocampal slices (D). Scale bars (black) = 300 μM; (white) = 2 mm.